Drug Screening Market Worth $8.63 Billion by 2022 | CAGR of 10.2%

Pune, India, 2020-Sep-29 — /EPR Network/ —

Fingerprint-based drug testing is a relatively new concept. It is non-invasive, less time consuming, portable, hygienic, user-friendly, and requires no specific preparation for sample collection and handling. This test is very easy to implement whenever and wherever it is required, thus offering flexible and effective means of supporting workplace drug testing policies.

Currently, the market for fingerprint-based drug testing is at its infancy stage and is expected to grow at a slower pace compared to other drug testing samples. Intelligent Fingerprint (UK) is the first player to gain entry into this market.

According to the new market research report by MarketsandMarkets,   The drug screening market was valued at USD 4.86 Billion in 2016 and is expected to reach USD 8.63 Billion by 2022, growing at a CAGR of 10.2% during the forecast period. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773

Based on product, the market is segmented into analytical instruments, rapid testing devices, and consumables. Rapid testing devices market is further subsegmented into urine testing devices and oral fluid testing devices. The urine testing devices segment is expected to account for the largest market share in 2017. However, the oral fluid testing devices segment is projected to register highest CAGR during the forecast period. The high growth in this segment is attributed to the benefits it offers such as shorter detection window, non-invasive nature, and low risk of sample tampering.

The global Drug Screening market by sample type is segmented into urine, breath, oral fluid, hair, and other samples. The urine sample segment is estimated to account for the largest share in 2017, however, the oral fluid samples segment is expected to register the highest growth rate during the forecast period.

Based on end users, the market is segmented into workplaces, criminal justice systems and law enforcement, drug treatment centers, pain management centers, schools and colleges, hospitals, individual users, and drug testing laboratories. In 2017, the workplace testing segment is expected to account for the largest share of the market. The growth of this end-user segment can be attributed to the growing safety concerns in the workplace and the increasing number of organizations that have made regular drug screening mandatory

North America accounted for the largest share of the Drug Screening Market : 

The market is dominated by North America, followed by Europe, Asia Pacific, and the Rest of the World (RoW). The dominance of the North American market is attributed to factors such as rising consumption of illicit drugs, availability of government funding to curb drug abuse, and the presence of laws supporting drug screening, and growing burden of accidents due to unsafe levels of alcohol consumption

Request for Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773

Key Market Players :

Prominent players offering drug screening products include Alere (US), Thermo Fisher (US), Drägerwerk (Germany), OraSure (US), Alfa Scientific Designs (US), Lifeloc (US), MPD, Inc. (US), Premier Biotech (US), Shimadzu (Japan), Siemens Healthineers (US). While, LabCorp (US), Quest Diagnostics (US), Omega Laboratories (US), Psychemedics (US), CRL (US), SureHire (Canada), and CannAmm (Canada) are some of key players offering drug screening services.